<DOC>
	<DOCNO>NCT02614846</DOCNO>
	<brief_summary>This study evaluate safety efficacy 6 week dose Hetrombopag Olamine Chronic Idiopathic Thrombocytopenic Purpura Patients . All subject study receive Hetrombopag .</brief_summary>
	<brief_title>Safety Efficacy Study Hetrombopag Olamine Chronic Idiopathic Thrombocytopenic Purpura ( ITP ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<criteria>1 . Confirmed diagnosis chronic ITP , peripheral blood smear bone marrow examination support diagnosis ITP evidence cause thrombocytopenia . 2 . Patients platelet count le 30,000/µL screening period baseline . 3 . Subjects refractory relapse least one prior ITP therapy . 4 . Previous therapy ITP include rescue must complete least 2 week prior randomization . 5 . Subjects treat maintenance immunosuppressive therapy must receive dose stable least 1 month . 6 . A complete blood count ( CBC ) , within reference range , follow exception . Platelets &lt; 30×109/L required inclusion . Hemoglobin : female males 10.0 g/dl eligible inclusion . Absolute neutrophil count ( ANC ) ≥1500/µL ( 1.5×109/L ) require inclusion . 7.PT result exceed normal ±3s , APTT result exceed normal ±10s . 8.Female subject negative result HCG test screen period baseline . 1 . Patients prior history arterial venous thrombosis，or diagnosis Thrombophilia . 2 . Subjects diagnose tumor . 3 . Have preexist cardiac disease within last 3 months.No arrhythmia know increase risk thrombolic event ( e.g . atrial fibrillation ) , patient Corrected QT interval ( QTc ) &gt; 450msec QTc &gt; 480 patient Bundle Branch Block . 4 . Female subject nurse pregnant screen predose baseline . 5 . Treatment thrombopoietin investigational drug within 30 day five halflives ( whichever longer ) precede first dose study medication . 6 . Treatment Rituximab Splenectomy within lat 6 month . 7 . Subjects previously receive eltrombopag thrombopoietin receptor agonist within 30 day five halflives ( whichever longer ) . 8 . Subject consume aspirin , aspirincontaining compound , salicylate , anticoagulant , quinine nonsteroidal antiinflammatories ( NSAIDs ) &gt; 3 consecutive day within 2 week study start end study . 9 . Any laboratory clinical evidence HIV infection.Any clinical history hepatitis C infection ; chronic hepatitis B infection ; evidence active hepatitis time subject screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>